Aerie Pharma (AERI) Price Target Lowered to $27 at RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Canaccord Genuity Downgrades Aerie Pharma (AERI) to Hold
April 24, 2015 7:52 AM EDTCanaccord Genuity downgraded Aerie Pharma (NASDAQ: AERI) from Buy to Hold.
For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.
Shares of Aerie Pharma closed at $35.39 yesterday.
... MoreCantor Fitzgerald Downgrades Aerie Pharma (AERI) to Hold
April 24, 2015 6:38 AM EDTCantor Fitzgerald downgraded Aerie Pharma (NASDAQ: AERI) from Buy to Hold.
For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.
Shares of Aerie Pharma closed at $35.39 yesterday.
... MoreAerie Pharmaceuticals (AERI) RhopressaTM Phase 3 Trial Fails to Meet Primary Endpoint
April 23, 2015 4:06 PM EDTAerie Pharmaceuticals, Inc. (NASDAQ: AERI) reported the results of its first Phase 3 registration trial (Rocket 1) for RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial did... More
